Sebela Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sebela Pharmaceuticals, Inc.
Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations.
Private Company Edition: Newpath Partners’ second fund totals $350m, Merck KGaA committed €600m to M Ventures, Eir Ventures raised €122.3m and Breakout Ventures has $112.5m. Recent financings were led by SOTIO ($317.5m), Odyssey ($218m), Avistone ($200m) and Acepodia ($109m).
New FDA assays may show whether polyethylene glycol laxative leaves toxic analytes and metabolites in children with chronic constipation – with potential implications for numerous other products.
Keeping Track: Keytruda Adds TNBC Claim; Finerenone, Brincidofovir, HTX-011 Submitted; CRL For Supernus’ ADHD Drug
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Braintree Laboratories Inc.